WAP
ZVRA icon

Wealthcare Advisory Partners’s Zevra Therapeutics ZVRA Stock Holding History

Wealthcare Advisory Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$1K – 1925
2021
Q1 		$1K Buy
+100
New +$873 ﹤0.01% 2034

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Wealthcare Advisory Partners's ZVRA Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Zevra Therapeutics (ZVRA) in Q2 2021, closing a stake of 100 shares — an estimated $1K sold.

Wealthcare Advisory Partners first reported a position in ZVRA in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 70 funds tracked by Wall St. Rank hold ZVRA as of Q2 2021.

  • Wealthcare Advisory Partners reported no remaining Zevra Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 100 Zevra Therapeutics shares in Q2 2021, an estimated $1K.
  • Wealthcare Advisory Partners first reported a position in Zevra Therapeutics in Q1 2021 and held it in 1 quarter.
  • Wealthcare Advisory Partners's Zevra Therapeutics position peaked at $1K in Q1 2021.
  • 70 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.